According to Fortune Business Insights, the global lutetium-177 market size was valued at USD 2.73 billion in 2025. The market is projected to grow from USD 3.43 billion in 2026 to USD 14.7 billion by 2034, exhibiting a CAGR of 19.95% during the forecast period. North America dominated the lutetium-177 market with a market share of 80.95% in 2025.
Lutetium-177 is a radioactive isotope widely used in targeted radionuclide therapy for the treatment of various cancers, particularly neuroendocrine tumors and prostate cancer. The increasing prevalence of cancer worldwide and the growing adoption of precision medicine are significantly driving the demand for lutetium-177-based therapies.
Key Market Drivers
Rising Prevalence of Cancer
The increasing incidence of neuroendocrine tumors and prostate cancer is driving demand for advanced targeted therapies such as lutetium-177 treatments.
Growing Adoption of Precision Medicine
Healthcare providers are increasingly focusing on personalized cancer treatment solutions, boosting the adoption of radioligand therapies.
Advancements in Nuclear Medicine
Technological advancements in radiopharmaceutical production and imaging technologies are supporting the development of innovative lutetium-177 therapies.
Market Restraints
Limited Availability of Radioisotopes
The production and supply of lutetium-177 require specialized nuclear facilities, which may limit market growth in certain regions.
High Treatment Costs
The high cost associated with radiopharmaceutical therapies and nuclear medicine procedures may restrict adoption in price-sensitive markets.
Get Sample Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/lutetium-177-market-112740
Market Opportunities
Increasing Research and Development Activities
Pharmaceutical and biotechnology companies are investing heavily in the development of new radioligand therapies for multiple cancer indications.
Expansion of Nuclear Medicine Infrastructure
Growing investments in healthcare infrastructure and nuclear medicine facilities are expected to create significant growth opportunities for the market.
Segmentation
By Drug
- LUTATHERA (lutetium Lu 177 dotatate)
- PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
- Others
By Age Group
- Adults
- Pediatrics
By Application
- Neuroendocrine Tumor
- Prostate Cancer
- Others
By End-User
- Hospitals
- Specialty Clinics
- Others
Regional Insights
North America
North America dominated the lutetium-177 market with a share of 80.95% in 2025 due to strong healthcare infrastructure, increasing adoption of nuclear medicine therapies, and the presence of leading pharmaceutical companies.
Europe
Europe is witnessing steady growth driven by increasing investments in oncology research and the growing availability of radiopharmaceutical therapies.
Asia Pacific
Asia Pacific is expected to experience significant growth during the forecast period due to rising cancer prevalence, improving healthcare infrastructure, and growing awareness regarding targeted cancer treatments.
Rest of the World
Latin America and the Middle East & Africa are also witnessing increasing adoption of nuclear medicine therapies supported by healthcare advancements and expanding oncology treatment facilities.
Get Sample Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/lutetium-177-market-112740
Key Players in the Lutetium-177 Market
- Novartis AG
- Curium Pharma
- Telix Pharmaceuticals Limited
- ITM Isotope Technologies Munich SE
- Lantheus Holdings, Inc.
- POINT Biopharma Global Inc.
- Eckert & Ziegler
- Bayer AG
- Radiopharm Theranostics
- Nusano Inc.
Conclusion
The global lutetium-177 market is expected to witness substantial growth through 2034, driven by the increasing prevalence of cancer, growing adoption of targeted radionuclide therapies, and advancements in nuclear medicine technologies. Rising investments in radiopharmaceutical research and expanding healthcare infrastructure are expected to further support market growth during the forecast period.